Paper · 35201490

Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study.

Murakami M and 14 others. Discov Oncol, 2022. Cited by 4 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study. Papers, record 35201490. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35201490

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study.; PubMed
Journal: Discov Oncol; PubMed
Year: 2022; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/35201490/; PubMed
DOI: https://doi.org/10.1007/s12672-021-00462-1; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC8777497/; PubMed
The journal: https://conductscience.org/library/journal-index/101775142; PubMed
Citations, by iCite: 4; iCite
Relative citation ratio, by iCite: 0.3; iCite
Revised in PubMed: 2022-02-26; PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Murakami M	Masatoshi
2	Fujimori N	Nao
3	Ohno A	Akihisa
4	Matsumoto K	Kazuhide
5	Teramatsu K	Katsuhito
6	Takamatsu Y	Yu
7	Takeno A	Ayumu
8	Oono T	Takamasa
9	Abe T	Toshiya
10	Ideno N	Noboru

1 to 10 of 15Source PubMed

See all 15 authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
JP19K17402	Japan Society for the Promotion of Science			PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	15,812,422	A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma.	Gastrointest Endosc	2005	https://conductscience.org/library/papers/15812422	PubMed
2	26,842,789	Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.	Cancer Chemother Pharmacol	2016	https://conductscience.org/library/papers/26842789	PubMed
3	19,690,548	A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.	Br J Cancer	2009	https://conductscience.org/library/papers/19690548	PubMed
4	26,495,775	Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study.	Pancreas	2016	https://conductscience.org/library/papers/26495775	PubMed
5	32,955,176	KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.	N Engl J Med	2020	https://conductscience.org/library/papers/32955176	PubMed
6	30,608,598	Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).	Jpn J Clin Oncol	2019	https://conductscience.org/library/papers/30608598	PubMed
7	33,082,211	Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.	Clin Cancer Res	2021	https://conductscience.org/library/papers/33082211	PubMed
8	32,640,720	Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis.	J Clin Med	2020	https://conductscience.org/library/papers/32640720	PubMed
9	31,892,339	Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.	World J Surg Oncol	2019	https://conductscience.org/library/papers/31892339	PubMed
10	23,247,983	CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.	Ann Surg Oncol	2013	https://conductscience.org/library/papers/23247983	PubMed

1 to 10 of 30

See all 30 references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMID	Title	Journal	Year	In Papers	Source
39,221,763	Prognostic value of neutrophil to lymphocyte ratio in patients with advanced pancreatic ductal adenocarcinoma treated with systemic chemotherapy.	Ann Med	2024	https://conductscience.org/library/papers/39221763	PubMed
37,504,335	Focus on Therapeutic Options for Surgically Resectable Pancreatic Adenocarcinoma Based on Novel Biomarkers.	Curr Oncol	2023	https://conductscience.org/library/papers/37504335	PubMed
36,597,515	Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management.	Cancer Manag Res	2022	https://conductscience.org/library/papers/36597515	PubMed

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ALB	213	PubTator's text mining	https://conductscience.org/library/genes/213	NCBI Gene
CRP	1,401	PubTator's text mining	https://conductscience.org/library/genes/1401	NCBI Gene
NFASC	23,114	PubTator's text mining	https://conductscience.org/library/genes/23114	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35201490

GET https://conductscience.org/api/papers/v1/35201490/references?page=2

API reference For AI assistants